Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis.
about
Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adultsLung transplantation for cystic fibrosisHuman neutrophil elastase-mediated cleavage sites of MMP-9 and TIMP-1: implications to cystic fibrosis proteolytic dysfunction.Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbationAnti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection.Breath sulfides and pulmonary function in cystic fibrosisClinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosisInflammation and airway microbiota during cystic fibrosis pulmonary exacerbationsUsing bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onsetPharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung diseasePotential of anti-inflammatory treatment for cystic fibrosis lung disease.Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation.Pediatrics, surfactant, and cystic fibrosis in AJRCCM 2003.Metabolomics analysis identifies novel plasma biomarkers of cystic fibrosis pulmonary exacerbation.Induction of type I interferon signaling by Pseudomonas aeruginosa is diminished in cystic fibrosis epithelial cells.Correlations of salivary biomarkers with clinical assessments in patients with cystic fibrosis.Inflammatory markers of lung disease in adult patients with cystic fibrosis.Changes of Proteases, Antiproteases, and Pathogens in Cystic Fibrosis Patients' Upper and Lower Airways after IV-Antibiotic TherapySputum induction improves detection of pathogens in children with cystic fibrosis.Down-regulation of IL-8 expression in human airway epithelial cells through helper-dependent adenoviral-mediated RNA interference.Clinical utility of C-reactive protein to predict treatment response during cystic fibrosis pulmonary exacerbationsAntipseudomonal Bacteriophage Reduces Infective Burden and Inflammatory Response in Murine Lung.New insights into pulmonary inflammation in cystic fibrosis.Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis.Sputum biomarkers of inflammation in cystic fibrosis lung diseasePotential role of high-mobility group box 1 in cystic fibrosis airway disease.Circulating RNA transcripts identify therapeutic response in cystic fibrosis lung diseaseA mass spectrometric method to simultaneously measure a biomarker and dilution marker in exhaled breath condensateProgress in cystic fibrosis and the CF Therapeutics Development NetworkMass spectrometric analysis of biomarkers and dilution markers in exhaled breath condensate reveals elevated purines in asthma and cystic fibrosis.Association between pulmonary function and sputum biomarkers in cystic fibrosis.Extracellular purines are biomarkers of neutrophilic airway inflammation.Urinary desmosine: a biomarker of structural lung injury during CF pulmonary exacerbation.Sputum desmosine during hospital admission for pulmonary exacerbation in cystic fibrosis.A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammationNovel outcome measures for clinical trials in cystic fibrosisEmerging Roles of Carbonyl Sulfide in Chemical Biology: Sulfide Transporter or Gasotransmitter?Biomarkers for cystic fibrosis drug development.Cystic Fibrosis: Microbiology and Host ResponseEffect of Media Modified To Mimic Cystic Fibrosis Sputum on the Susceptibility of Aspergillus fumigatus, and the Frequency of Resistance at One Center.
P2860
Q24187890-A7DA6557-C97B-42EB-8222-476F690EEA1CQ28749501-3B8278C4-1521-4C78-A60E-57C2EE6C95F8Q33611238-B19D63AE-CBC8-4600-B048-B760C5723A32Q33744911-C713570F-7291-4635-906D-5DC51ED16FF1Q33836925-E2249BF3-F007-4296-BF35-AED4BF7ED9D4Q34116010-2A4DB6D1-6B9D-4E3F-9339-3030880CFF67Q34480471-F8E1CAD5-2E35-410B-9F84-62A8B8C3BCB2Q34706914-532DC3F1-0630-422F-A02A-F9B29887748FQ35143420-022113F5-56C9-4CE3-AEA1-99B4177F6888Q35164509-BE31D78B-C928-45A6-9F91-07DB17B18F10Q35557381-44D36840-1B60-4E26-9AA0-09A879371448Q35565168-49C23B30-D948-4855-8A9F-6365DA791626Q35626617-D176ECEA-FBF9-43D6-A396-5823E0314CAFQ35675928-95658D13-B3E6-40B3-B1A0-A3432BA5F767Q35684772-186B64A3-DC45-489C-88D2-934DED888099Q35741301-E1A85987-7966-46DE-BF74-32AFA4B23F99Q35749974-37FFD6A4-ED1D-4704-84C5-FD18908CE34DQ35817400-4B57E19E-5203-4D56-BB8D-55DA21C27380Q35828811-16ADBAE5-B863-4468-BDCB-E4FC5B044DBDQ35836325-DE2DFEA2-FD3B-4533-B957-C03213CD2553Q36274154-71FC0BDB-8C8E-45BD-A432-305537C745ECQ36571855-04F693D0-2A37-42FC-B1A3-7323864D6A34Q36573117-4D3122F0-1CC1-482A-AEB6-572780051E61Q36771148-D0E2D912-8AC3-49B2-81A5-24E617735FE7Q36891552-0A94D155-3C74-4B7C-BE7E-E8730E210BFAQ36935244-11F2CCFD-2521-4B36-AD4C-5B2EB86B6634Q36960790-9DA1001B-40CF-4E6B-AFA3-7D7A791A6686Q36962710-0BBB711D-AF81-4270-8FA9-0AFC1D9C5542Q37209004-B3363445-47A9-49C9-9F5E-1C68E65DA517Q37218032-6720E4D1-75E6-4344-A535-0FB3D34C4BA4Q37287157-0154E794-499A-44FD-B39D-96ADB2C45D04Q37297168-E28498E4-F2AE-4A22-BF5C-24BECBB24239Q37377689-E99F29B8-6666-4A0B-8D42-947E38D29572Q37463875-04CE5A5F-A980-4125-A863-6C86CD556825Q37721498-270E5ACD-95CB-4D41-A723-8FE05E2A64C2Q38340406-3AD2926C-2B45-45FE-BD70-82B29116D45BQ38690809-10BC93D2-D6AE-4B88-B57A-C04656842122Q38755600-0341480A-A7B2-4A96-8902-5C241B487278Q38911644-B9FF685A-C722-484C-AB6D-D82E3F351433Q39514745-969C4CC7-F28D-472B-9E83-09B36E5AE55C
P2860
Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Inflammatory and microbiologic ...... ntibiotics in cystic fibrosis.
@en
Inflammatory and microbiologic ...... ntibiotics in cystic fibrosis.
@nl
type
label
Inflammatory and microbiologic ...... ntibiotics in cystic fibrosis.
@en
Inflammatory and microbiologic ...... ntibiotics in cystic fibrosis.
@nl
prefLabel
Inflammatory and microbiologic ...... ntibiotics in cystic fibrosis.
@en
Inflammatory and microbiologic ...... ntibiotics in cystic fibrosis.
@nl
P2093
P2860
P921
P1476
Inflammatory and microbiologic ...... ntibiotics in cystic fibrosis.
@en
P2093
Claudia L Ordoñez
Cori L Daines
Frank J Accurso
George Z Retsch-Bogart
James F Chmiel
Jane L Burns
Moira L Aitken
Nicole Mayer-Hamblett
Noreen R Henig
Ronald L Gibson
P2860
P304
P356
10.1164/RCCM.200306-731OC
P407
P577
2003-09-11T00:00:00Z